This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (59)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

BURTON W. ROCKLIFF, MD; EDWARD H. DAVIS, MD

Arch Neurol. 1966;15(2):129-136.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

TIC DOULOUREUX is an often incapacitating affliction for which no completely satisfactory medical treatment has been available. While early observations that diphenylhydantoin has beneficial effects have been generally confirmed,^1-4 results with this drug are variable. Low doses are often ineffective, while the high dosages sometimes required for symptom control are poorly tolerated.

Recently, Blom^5,6 and others^7-13 have reported that the paroxysmal pain of trigeminal neuralgia is promptly and consistently suppressed by the administration of carbamazepine (Tegretol), an iminostilbene derivative with anticonvulsant activity. Chemically, the compound is 5 carbamyl-5H-dibenz (b,f )-azepine, and, as indicated by the structural formula (Fig 1), it is related to the antidepressant imipramine, but not to the hydantoins. While results with carbamazepine in typical tic douloureux are reported to be highly promising, the benefits observed in postherpetic and atypical facial neuralgias have been minimal. No controlled clinical trials with carbamazepine have been reported. . . . [Full Text PDF of this Article]

Author Affiliations
LOS ANGELES

From the Medical Department, Western Section, Geigy Pharmaceuticals (Dr. Rockliff), and the Division of Medicine (Neurology), Cedars-Sinai Medical Center, and the Department of Neurology, University of Southern California School of Medicine (Dr. Davis), Los Angeles.

Footnotes
Submitted for publication March 23, 1966; accepted April 30.

Reprint requests to Geigy Pharmaceuticals, 5801 Sheila St, Los Angeles 90022 (Dr. Rockliff).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?